Evidence map›Paper›PMID 42337526›Full record

ReviewJournal of nanobiotechnology2026

Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine.

Na Liu, Shi Tang, Shasha Yu, Yang Song, Haishan Zhang, Yizi Wang

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Na Liu *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Shi Tang *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Shasha Yu *Department of Cardiology, The First Hospital of China Medical University, Shenyang, China.
Yang SongDepartment of Rheumatology and Immunology, Shengjing Hospital of China Medical University, 110021, Liaoning, Shenyang, P.R. China. songy18@sj-hospital.org.
Haishan ZhangDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, China. zhanghaishan99@sohu.com.
Yizi WangDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China. wangyz3@sj-hospital.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomedical nanorobots represent an emerging class of active nanosystems that enable controlled navigation, sensing, and targeted intervention within complex biological environments. This review presents recent developments in nanorobot design, highlighting key material architectures, including inorganic, soft, hybrid, and biohybrid systems and their modular integration for biomedical functionality. Major propulsion and control strategies, such as chemical, magnetic, and acoustic actuation, are discussed alongside emerging capabilities in environmental sensing, swarm intelligence, and AI-assisted control. Applications in regenerative medicine and MIIs are examined, with emphasis on targeted drug delivery, tissue repair, and theranostic systems across diverse disease contexts. Despite promising preclinical progress, significant translational challenges remain, including biological interactions, long-term biosafety, manufacturing scalability, and regulatory uncertainty. Finally, we outline key research priorities, including the development of biodegradable systems, standardized evaluation frameworks, and integration with imaging and digital medicine, to facilitate the safe and effective clinical translation of nanorobotics.

Indexed as

NanotechnologyRegenerative MedicineRoboticsAnimalsAutonomous RobotsDrug Delivery SystemsHumansNanomedicineBiohybrid nanorobotsBiomedical nanotechnologyMinimally invasive interventionsNanoroboticsRegenerative medicineTargeted drug delivery

Identifiers

PMID42337526
PMCPMC13495297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.